Patents by Inventor Lisa Ellerby

Lisa Ellerby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220251564
    Abstract: A p16INK4a inhibitor, a composition that includes the p16INK4a inhibitor, or a pharmaceutical composition that includes the p16INK4a inhibitor, for use in the prevention and/or the treatment of Huntington's disease, wherein the p16INK4a inhibitor is a nucleic acid or a peptide, a small compound molecule or a marketed drug.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 11, 2022
    Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Christian NERI, Francesca FARINA, Jessica VOISIN, Lisa ELLERBY
  • Publication number: 20120129834
    Abstract: Methods are provided for the treatment and/or prophylaxis of Huntington's disease. In various embodiments the methods involve administration of one or more serotonin receptor antagonists. In certain embodiments the serotonin receptor antagonists include, but are not limited to loxapine, and/or a loxapine analogue, and/or cyproheptadine, and/or a cyproheptadine analogue (e.g., pizotifen).
    Type: Application
    Filed: September 16, 2011
    Publication date: May 24, 2012
    Applicant: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: ROBERT HUGHES, LISA ELLERBY
  • Publication number: 20080188421
    Abstract: The present invention provides homing conjugates containing an antimicrobial peptide and a tumor homing molecule, wherein the tumor homing molecule comprises a dimer of two endothelium-homing peptide monomers, wherein the conjugate homes to and is internalized by a tumor cell type or tissue comprising angiogenic endothelial cells and exhibits high toxicity thereto, wherein the high toxicity is due to disruption of mitochondrial membranes, and wherein the antimicrobial peptide has low mammalian cell toxicity when not linked to said tumor homing molecule. The present invention is based, in part, on the discovery that dimerization of endothelium-homing peptide monomer confers greatly increased cytotoxic activity on the conjugate.
    Type: Application
    Filed: March 31, 2005
    Publication date: August 7, 2008
    Inventors: Dale E. Bredesen, Michael Ellerby, Lisa Ellerby
  • Patent number: 5200334
    Abstract: An active biological material encapsulated in a glass is formed using a sol-gel process. A metal alkoxide is mixed with water and exposed to ultrasonic energy at a pH.ltoreq.2 to form a single phase solution which is then buffered to a pH between about 5 and 7. The buffered solution is then mixed with the active biological material and the resultant gel is aged and dried. The dried product is a transparent porous glass with substantially all of the added active biological material encapsulated therein, the biological material retaining a high level of activity.
    Type: Grant
    Filed: August 13, 1991
    Date of Patent: April 6, 1993
    Assignee: The Regents of the University of California
    Inventors: Bruce S. Dunn, Joan S. Valentine, Jeffrey I. Zink, Lisa Ellerby, Fumito Nishida, Clinton Nishida, Stacey A. Yamanaka